Emerald Investment Advisers LLC Purchases Shares of 9,275 United Therapeutics Corporation $UTHR

Key Points

• Emerald Investment Advisers acquired 9,275 shares of United Therapeutics in the second quarter, valued at approximately $5.0 million. Institutional investors collectively own 94.08% of the company.
• United Therapeutics reported quarterly EPS of $7.27, exceeding the $6.86 consensus estimate, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
• Analysts maintain a positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $646, despite the stock opening at $513.12 and recent insider sales totaling $239.3 million.

Emerald Investment Advisers LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,275 shares of the biotechnology company's stock, valued at approximately $5,025,000.

Several other hedge funds have also bought and sold shares of the stock. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock worth $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $277,000. Cerity Partners LLC grew its holdings in shares of United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock valued at $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia grew its holdings in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at $10,311,581.28. This trade represents a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 442,575 shares of company stock worth $239,326,330 over the last quarter. 8.60% of the stock is currently owned by insiders.

United Therapeutics Stock Down 1.5%

NASDAQ UTHR opened at $513.12 on Friday. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35. The firm has a market capitalization of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.76 and a beta of 0.59. The company has a fifty day moving average of $533.08 and a two-hundred day moving average of $537.36.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.41 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source